My Passport
News and Commentary education Live Coronavirus Dashboard
S&P 500 ETF
0.00%
NASDAQ ETF
0.00%
Dow Jones ETF
0.00%


Netflix Q4 To Show Advertising, Live Sports S...
Goldman Sachs Raises Spotify's Forecast Ahead...
'No Rate Cuts In Q1 2025,' Strategist Says Af...
Pinterest Headwinds See BofA Lower Estimates,...
Wall Street Bullish on Nvidia Following Advan...
Bird Flu Sparks Vaccine Stock Surge: ETFs To...
Fed Minutes Reveal Inflation Jitters, Policym...
Honda, Amazon Collaborate On EV Development W...
The Rise of the Solo General Partner Investor

While modern day venture capital originated in the 1940s, the very first iteration of venture capital (VC) investments--where a general partner (GP) investments capital on behalf of a limited partner (LP)--dates all the way back to the early 1600s with the founding of East India...

  • How are Higher Rates Impacting the Housi...
  • Quantitative Tightening: How the Fed Co...
  • Should Investors Worry About Inflation?
  • How Semiconductors are Made and Why its...
  • What Are NFTs?
    • Inflation: What is it and How to Protect From...
    Short Squeezes Could Lead to Market Dislocati...
    How Google and Facebook Antitrust Lawsuits Co...
    Vaccine News Triggers Growth to Value Rotatio...
    Energy
    Materials
    Industrial
    Finance
    Consumer D...
    Consumer S...
    Informatio...
    Telecommun...
    Health Car...
    Utilities
    Oil
    Gold
    ETFs IPOs Ratings
     
    S&P 500 ETF
    0.00%
    NASDAQ ETF
    0.00%
    Dow Jones ETF
    0.00%
    Search
    News and Commentary
    Education
    Market
    ETFs
    IPOs
    Ratings
    Newsfeed
    My passport
    Login
    Sign up

    NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) (NYSE: NVS)

    Overview
    current price
    $99.25
    $99.25
    change
    -0.97 | -0.97%
    -0.97 | -0.97%
    Yesterday's Close
    100.22
    open
    99.47
    volume
    1.06 M
    30d. avg volume.
    1.10 M
    1 day
    99.04 - 99.72
    52 weeks
    92.35 - 120.92
    p/e
    0.00
    beta
    0.5692
    market cap
    0.00 B
    dividend yield
    0.00%
    Industry
    -
    NVS by TradingView
    News and Commentary
    US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could... Monday, the U.S. Department of Health and Human Services (HHS) announced that Medicare enrollees will benefit from reduced prices on 54 drugs through Medicare Part B, effective f...
    Novartis' Q2 Earnings: Revenue And EPS Beat, Raises 2024 Profit Forecast On Strong Demand For Key Dr... Swiss pharma giant Novartis AG (
    Market Update: S&P 500, Nasdaq Retreat, Dow Climbs 200 Points on Stock Rotation The S&P 500 Index and Nasdaq Composite slipped lower on Wednesday as investors rotated out of semiconductor names and into more rate sensitive names. This, in turn, lead the Dow...
    After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stol... U.S. drug wholesaler Cencora Inc (
    Google DeepMind Develops Latest AI Model To Aid Scientists In Fighting Disease Researchers at Alphabet Inc's (
    Market Update: Dow Climbs 260 Points on Strong Second-Quarter Earnings Stocks climbed higher on Tuesday as the second-quarter earnings season delighted investors, helping to build on gains from the prior session. The Dow Jones Industrial Average ros...
    Amazon, Alphabet, Meta, Intel Q3 Earnings This Week: Will Mega-Caps Shatter Forecasts And Revive Mar... After the first week of earnings, analysts have tempered their expectations for profit growth, anticipating a continuation of the profit-declining trend.
    Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administrati...
    Novartis Sandoz Prepares For Public Debut With Strong Sales Record And Plans for New Biologic Drugs Novartis AG (NVS 
    From Years to Months: How AI is Shaping the Landscape of Clinical Trials Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significan...
    StockTwits
    StockTwits
    Most Shared
    Rivian's Strong Deliveries, R2 Line Plans And VW JV Expansion Drive Analyst Optimism
    Apple's iPhone 16 Stumbles On 'Intelligence' Awareness, But Pro Max Shines Bright: Analyst
    BoFA Expects Delta to Maintain 10% EPS Growth in 2025, Sees Strong Q4 Result
    Most Popular
    Tesla Analysts On Deliveries: EV Stock Could Have 'Stormy Weather' In Short Term, 'Generational Set Of Growth Opportunities' Long Term
    Toyota 2024 US Sales Surge 3.7%, Hits Milestone With Over A Million Electrified Vehicles Sold
    JetBlue Fined $2 Million For 'Chronic Flight Delays': Delta, United Rank Among Most On-Time Airlines
    popular tags
    Earnings
    Coronavirus
    Apple
    Amazon
    Coronavirus Impact
    Covid-19
    Google
    Tesla
    Covid19
    mobile iOS
    social Facebook Twitter Youtube Linkedin Rss Google News
    Passport to Wall Street About Us Contact Advertise Privacy Policy Terms of Service
    Sign Up
    © 2025 Passport to Wall Street
    Quotes are at least 20 minutes delayed

    Join now and unlock premium features

    Already Have An Account?